Barriers to care and treatment for patients with chronic viral hepatitis in Europe: A systematic review

Liver International

Volumn 34, Issue 10, 2014, Pages 1452-1463

  Papatheodoridis, George V ^a   Tsochatzis, Emmanuel ^b   Hardtke, Svenja ^c   Wedemeyer, Heiner ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Barriers; Hepatitis B; Hepatitis C; Treatment

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RNA;

ALCOHOL ABUSE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; DRUG USE; EUROPE; FINANCIAL MANAGEMENT; HEALTH CARE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMIGRANT; MEDICATION COMPLIANCE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); PATIENT ATTITUDE; PATIENT CARE; RESOURCE ALLOCATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT REFUSAL; ADULT; ECONOMICS; HEALTH CARE DELIVERY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MIGRANT; STATISTICS AND NUMERICAL DATA;

ADULT; EMIGRANTS AND IMMIGRANTS; EUROPE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS;

EID: 84908145045     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12565     Document Type: Review

References (53)

1. World Health Organization. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Geneva: WHO, 2012.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
3. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011; 18(Suppl. 1): 1-16.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
5. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 167-78.
6. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
8. European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
10. Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18: 6060-9.
11. Wedemeyer H. Hepatitis C in 2012: on the fast track towards IFN-free therapy for hepatitis C? Nat Rev Gastroenterol Hepatol 2013; 10: 76-8.
12. Deuffic-Burban S, Mathurin P, Valleron AJ. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res 2009; 18: 233-52.
13. Sypsa V, Touloumi G, Papatheodoridis GV, et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005; 12: 543-50.
14. Cohen C, Holmberg SD, McMahon BJ, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 2011; 18: 377-83.
15. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl. 1): 151-6.
16. Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 2012; 26: 371-80.
17. Angeli E, Mainini A, Meraviglia P, et al. Eligibility and feasibility of the treatment of chronic hepatitis C in a cohort of Italian HIV-positive patients at a single HIV reference center. AIDS Patient Care STDS 2011; 25: 295-301.
18. Antonucci G, Mazzotta F, Puoti M, et al. Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. J Viral Hepat 2012; 19: 881-9.
19. Backmund M, Meyer K, Von ZM, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
20. Cacoub P, Halfon P, Rosenthal E, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol 2008; 48: 35-42.
21. Cullen W, Stanley J, Langton D, Kelly Y, Bury G. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative. Eur J Gen Pract 2007; 13: 5-12.
22. Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17: 435-43.
23. Delwaide J, El SR, Gerard C, Belaiche J. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005; 17: 1185-9.
24. Ena J, Ruiz-de-Apodaca RF, Pasquau F, Amador C, Benito C. Cross-sectional epidemiology of hepatitis C virus detection and treatment in HIV-infected patients. Eur J Intern Med 2011; 22: 66-72.
25. Gazdag G, Horvath G, Szabo O, Ungvari GS. Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacol Hung 2010; 12: 459-62.
26. Gheorghe L, Pascu O, Ceausu E, et al. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009. J Gastrointestin Liver Dis 2010; 19: 161-7.
27. Hatem C, Minello A, Bresson-Hadni S, et al. Is the management of hepatitis C patients appropriate? A population-based study Aliment Pharmacol Ther 2005; 21: 1007-15.
28. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
29. Lutgehetmann M, Meyer F, Volz T, et al. Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany. Z Gastroenterol 2010; 48: 1126-32.
30. Mocroft A, Rockstroh J, Soriano V, et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38: 1092-7.
31. Monnet E, Collin-Naudet E, Bresson-Hadni S, et al. Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study. J Hepatol 2006; 44: 499-506.
32. Overbeck K, Bruggmann P, Helbling B. Chronic hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment? Eur J Gen Pract 2011; 17: 103-8.
33. Papadopoulos N, Manolakopoulos S, Deutsch M, et al. Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol 2013; 25: 587-93.
34. Parkes J, Roderick P, Bennett-Lloyd B, Rosenberg W. Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom. BMC Public Health 2006; 6: 3.
35. Sene D, Pol S, Piroth L, et al. Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study. Epidemiol Infect 2007; 135: 409-16.
36. Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol 2009; 81: 1999-2006.
37. Stroffolini T, D'Egidio PF, Aceti A, et al. Hepatitis C virus infection among drug addicts in Italy. J Med Virol 2012; 84: 1608-12.
38. Stroffolini T, Spadaro A, Di Marco V, et al. Current practice of chronic hepatitis B treatment in Southern Italy. Eur J Intern Med 2012; 23: e124-7.
39. Stroffolini T, Spadaro A, Guadagnino V, et al. Current practice of hepatitis C treatment in Southern Italy. Dig Liver Dis 2010; 42: 822-5.
40. Tedder RS, Rodger AJ, Fries L, et al. The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis 2013; 56: 951-60.
41. Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010; 2010: DOI:10.1155/2010/261472. Article ID 261472.
42. Mitchell AE, Colvin HM, Palmer BR. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729-33.
43. Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012; 6: 285-95.
44. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56: 320-5.
45. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14: 6902-10.
46. Leblebicioglu H, Arama V, Causse X, et al. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat 2014; 21: 662-670.
47. Giannousis IP, Papatheodoridis GV, Deutsch MJ, et al. The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. Eur J Gastroenterol Hepatol 2010; 22: 172-9.
48. Chu JJ, Wormann T, Popp J, et al. Changing epidemiology of hepatitis B and migration - a comparison of six Northern and North-Western European countries. Eur J Public Health 2013; 23: 642-7.
49. Talal AH, LaFleur J, Hoop R, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013; 37: 473-81.
50. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
51. Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-44.
52. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(Suppl. 2): S39-45.
53. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598-609.